Business, energy, technology, markets and global industry news from Business News Today

Wegovy

PharmaDeviceNews Wegovy
Representative image showing oral weight loss medication with a measuring tape and water glass in the background, illustrating the growing shift from injectable GLP-1 therapies to convenient, daily oral treatments like orforglipron.
Features & Analysis

Can oral GLP-1s maintain weight loss after injectables? Lilly’s orforglipron may prove it can

Eli Lilly and Company (Lilly) has reported positive topline results from the ATTAIN-MAINTAIN Phase 3 trial evaluating orforglipron, its once-daily oral glucagon-like peptide-1 (GLP-1) receptor agonist, for maintenance of weight loss in patients previously treated with injectable incretins. The trial enrolled participants who had completed 72 weeks of treatment with semaglutide (Wegovy) or tirzepatide (Zepbound)

Read More
Novo Nordisk’s higher-dose Wegovy nears EU launch with 20.7% weight loss
Pharma & Biotech

Can Novo Nordisk’s semaglutide 7.2 mg set a new standard in obesity treatment?

Novo Nordisk's semaglutide 7.2 mg achieves 20.7% weight loss. Find out what this EU regulatory step means for obesity treatment and patient outcomes in 2026.

Read More
Novo Nordisk is seeking approval for 7.2 mg Wegovy (semaglutide) from the FDA .
Pharma & Biotech

Can higher-dose Wegovy reshape the obesity treatment curve for Novo Nordisk?

Novo Nordisk’s semaglutide 7.2 mg dose aims to raise Wegovy’s weight loss impact. Learn how this could shift obesity treatment and reshape clinical norms.

Read More